Hudson Canyon Capital Management’s Biogen BIIB Stock Holding History

Hudson Canyon Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,025	Closed	-$1.86M	–	56
2024 Q2	$1.86M	Buy	8,025 +325	+4%	+$70.6K	1.26%	30
2024 Q1	$1.66M	Hold	7,700	–	–	1.07%	45
2023 Q4	$1.99M	Hold	7,700	–	–	1.45%	32
2023 Q3	$1.98M	Buy	7,700 +2,885	+60%	+$772K	1.62%	22
2023 Q2	$1.37M	Sell	4,815 -153	-3%	-$45.5K	1.08%	53
2023 Q1	$1.38M	Buy	4,968 +968	+24%	+$268K	1.16%	53
2022 Q4	$1.11M	Buy	4,000 +1,250	+45%	+$353K	1.02%	54
2022 Q3	$734K	Buy	+2,750	New	+$584K	0.73%	55
2022 Q2	–	Sell	-6,027	Closed	-$1.27M	–	56
2022 Q1	$1.27M	Hold	6,027	–	–	1%	55
2021 Q4	$1.45M	Sell	6,027 -298	-5%	-$76.6K	1.05%	54
2021 Q3	$1.79M	Hold	6,325	–	–	1.38%	36
2021 Q2	$2.19M	Sell	6,325 -25	-0.4%	-$7.57K	1.64%	25
2021 Q1	$1.78M	Buy	6,350 +527	+9%	+$142K	1.39%	36
2020 Q4	$1.43M	Buy	+5,823	New	+$1.5M	1.13%	55

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hudson Canyon Capital Management's BIIB Position: Q3 2024 in Review

Hudson Canyon Capital Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 8,025 shares — an estimated $1.86M sold.

Hudson Canyon Capital Management first reported a position in BIIB in Q4 2020 and held it in 14 quarters. The position peaked at $2.19M in Q2 2021. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Hudson Canyon Capital Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Hudson Canyon Capital Management sold 8,025 Biogen shares in Q3 2024, an estimated $1.86M.
Hudson Canyon Capital Management first reported a position in Biogen in Q4 2020 and held it in 14 quarters.
Hudson Canyon Capital Management's Biogen position peaked at $2.19M in Q2 2021.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Hudson Canyon Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.